Progyny, Inc. (NASDAQ:PGNY – Get Free Report) insider Geoffrey Clapp sold 774 shares of the business’s stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $36.41, for a total transaction of $28,181.34. Following the completion of the transaction, the insider owned 58,235 shares in the company, valued at $2,120,336.35. The trade was a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Progyny Price Performance
Shares of PGNY stock traded down $0.40 during trading on Friday, hitting $36.18. 869,008 shares of the stock traded hands, compared to its average volume of 1,062,968. Progyny, Inc. has a 52-week low of $16.10 and a 52-week high of $37.15. The firm has a market capitalization of $2.66 billion, a P/E ratio of 33.19, a price-to-earnings-growth ratio of 1.70 and a beta of 0.97. The firm’s fifty day moving average price is $28.48 and its 200-day moving average price is $24.87.
Progyny (NASDAQ:PGNY – Get Free Report) last issued its quarterly earnings data on Wednesday, November 4th. The company reported $0.52 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.21. The company had revenue of $341.25 million during the quarter, compared to analyst estimates of $340.76 million. Progyny had a return on equity of 19.82% and a net margin of 6.80%. The firm’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period in the prior year, the business posted $0.15 earnings per share. As a group, equities research analysts expect that Progyny, Inc. will post 1.41 earnings per share for the current year.
Institutional Investors Weigh In On Progyny
A number of institutional investors have recently modified their holdings of PGNY. Toth Financial Advisory Corp lifted its position in shares of Progyny by 21.3% during the 3rd quarter. Toth Financial Advisory Corp now owns 2,735 shares of the company’s stock worth $69,000 after purchasing an additional 480 shares during the last quarter. Hantz Financial Services Inc. grew its stake in shares of Progyny by 14.4% during the third quarter. Hantz Financial Services Inc. now owns 4,124 shares of the company’s stock worth $104,000 after purchasing an additional 520 shares in the last quarter. Oregon Public Employees Retirement Fund grew its stake in shares of Progyny by 4.2% during the third quarter. Oregon Public Employees Retirement Fund now owns 17,254 shares of the company’s stock worth $435,000 after purchasing an additional 700 shares in the last quarter. Public Employees Retirement System of Ohio acquired a new position in shares of Progyny during the second quarter worth $29,000. Finally, State of Wyoming increased its holdings in Progyny by 3.5% in the third quarter. State of Wyoming now owns 29,806 shares of the company’s stock valued at $751,000 after buying an additional 1,015 shares during the last quarter. 94.93% of the stock is owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on PGNY shares. Cantor Fitzgerald increased their price target on Progyny from $31.00 to $35.00 and gave the stock an “overweight” rating in a report on Thursday, November 5th. Truist Financial boosted their price objective on shares of Progyny from $33.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Jefferies Financial Group set a $33.00 target price on shares of Progyny in a research report on Tuesday, September 8th. Wall Street Zen raised shares of Progyny from a “buy” rating to a “strong-buy” rating in a research note on Sunday, November 8th. Finally, Wells Fargo & Company lifted their price target on shares of Progyny from $37.00 to $38.00 and gave the company an “overweight” rating in a research report on Thursday, November 5th. Eleven investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Progyny currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.33.
Get Our Latest Research Report on PGNY
About Progyny
Progyny, Inc. provides fertility and family-building benefits to employers and their employees. Its services are designed to help members navigate care options, access fertility specialists and receive support throughout treatment. The company’s offerings include coverage for treatments such as in vitro fertilization and egg freezing, along with fertility medications through its pharmacy benefit. Progyny also supports other family-building paths, including adoption and surrogacy, depending on the plan selected by an employer.
Recommended Stories
- Five stocks we like better than Progyny
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Progyny Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progyny and related companies with MarketBeat.com's FREE daily email newsletter.
